Parshuram Christopher S, Joffe Ari R
Department of Pediatrics, University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.
Pediatr Crit Care Med. 2003 Jan;4(1):65-8. doi: 10.1097/00130478-200301000-00013.
Transfusion of packed red blood cells containing high concentrations of potassium have been associated with fetal and neonatal arrhythmia and hyperkalemic cardiac arrest. This study sought to determine the biochemical and associated clinical effects of packed red blood cells transfusion in critically ill children.
Prospective case series.
Tertiary multidisciplinary university hospital pediatric intensive care unit.
Consecutive sample of 28 children 2.7-27 kg (1 wk to 12 yrs old) receiving a packed red blood cell transfusion.
None.
Potassium concentration was prospectively measured from packed red blood cell transfusions. Adverse events were recorded during and for 4 hrs following transfusion including hyperkalemia, therapy for hyperkalemia, arrhythmia, cardiac arrest, and death. There were 54 packed red blood cell transfusions (mean volume of 11.8 +/- 2.8 mL/kg). The measured packed red blood cell potassium concentration was > 25 mmol/L in 16, 15-25 mmol/L in 11, and < 15 mmol/L in 25. The mean patient potassium concentrations before (3.85 +/- 0.55, range 2.7-5.2 mmol/L) and after transfusion (3.94 +/- 0.62, range 2.8-5.7 mmol/L) were not significantly different. There was no therapy required for hyperkalemia, no new arrhythmia, no cardiopulmonary arrest, and no deaths during and up to 4 hrs following transfusion. Of the six children given a bolus of packed red blood cells (> or = 5 mL/kg over < 10 mins), the maximum increase in patient potassium concentration was 0.8 mmol/L, in a child who had an initial potassium concentration of 2.7 mmol/L. No patient's potassium concentration was > 5 mmol/L following rapid transfusion.
This prospective study found no significant change in patient potassium concentration and no acute adverse events related to transfusion in critically ill children, including those receiving packed red blood cells by bolus. Larger prospective studies are required to evaluate the acute effects of rapid and central venous transfusion in critically ill children.
输注含高浓度钾的浓缩红细胞与胎儿及新生儿心律失常和高钾血症性心脏骤停有关。本研究旨在确定危重症儿童输注浓缩红细胞的生化及相关临床影响。
前瞻性病例系列研究。
三级多学科大学医院儿科重症监护病房。
连续选取28例接受浓缩红细胞输注的儿童,年龄2.7 - 27千克(1周龄至12岁)。
无。
前瞻性测量浓缩红细胞输注中的钾浓度。记录输血期间及输血后4小时内的不良事件,包括高钾血症、高钾血症治疗、心律失常、心脏骤停和死亡。共进行了54次浓缩红细胞输注(平均输注量为11.8±2.8毫升/千克)。测得的浓缩红细胞钾浓度>25毫摩尔/升的有16次,15 - 25毫摩尔/升的有11次,<15毫摩尔/升的有25次。输血前患者平均钾浓度(3.85±0.55,范围2.7 - 5.2毫摩尔/升)与输血后(3.94±0.62,范围2.8 - 5.7毫摩尔/升)无显著差异。输血期间及输血后4小时内,无高钾血症治疗需求,无新发心律失常,无心肺骤停,无死亡。在6例接受大剂量浓缩红细胞输注(<10分钟内输注≥5毫升/千克)的儿童中,初始钾浓度为2.7毫摩尔/升的1例儿童,患者钾浓度最大升高0.8毫摩尔/升。快速输血后无患者钾浓度>5毫摩尔/升。
这项前瞻性研究发现,危重症儿童患者的钾浓度无显著变化,且未发生与输血相关的急性不良事件,包括接受大剂量输注浓缩红细胞的儿童。需要开展更大规模的前瞻性研究来评估危重症儿童快速及中心静脉输血的急性影响。